Mostrar el registro sencillo del ítem

dc.contributor.authorBastidas Goyes, Alirio
dc.contributor.authorTorres Arevalo, Daniela
dc.date.accessioned2023-09-04T16:12:30Z
dc.date.available2023-09-04T16:12:30Z
dc.date.issued2023-08-08
dc.identifier.urihttp://hdl.handle.net/10818/56712
dc.description29 páginases_CO
dc.description.abstractBackground: In Colombia, there are no records showing long-term survival data for Community Acquired Pneumonia (CAP). Therefore, survival and risk factors in patients with this condition who required hospitalization are described. Methods: A retrospective cohort study was conducted in a high-complexity care center in Colombia, evaluating survival at 3, 6, and 12 months in CAP patients, using the Kaplan Meier method. Stratifications were made by age, sex, comorbidity, and severity. The comparison of survival curves was performed using the Log-Rank test, a multivariate analysis with Cox regression was performed to study possible risk factors that affected 12- month survival in patients with CAP. Results: 3688 subjects were admitted, with a mortality of 16.3% per year. Survival at three, six, and twelve months was 93.1%, 88.9%, and 84.5%, respectively. Analysis stratified by pneumonia severity index (PSI), 12-month survival was 98.7% in class-I, 95.6% in class-II, 87.41% in class-III, 77.1% in class IV, and 65.8% in class-V (p<0.001). Cox-regression showed that being male (HR: 1.44; 95% CI: 1.22-1.70; 0<0.001), an elevated PSI (HR: 4.22; 95%CI: 1.89-9.43; p<0.001), a high comorbidity index (HR: 2.29; 95%CI: 1.89-2.84; p<0.001) and vasopressor requirement (HR: 2.22; 95%CI <0.001) were associated with a lower survival at twelve months of follow-up.en
dc.formatapplication/pdfes_CO
dc.language.isoenges_CO
dc.publisherUniversidad de La Sabanaes_CO
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceUniversidad de La Sabana
dc.sourceIntellectum Repositorio Universidad de La Sabana
dc.subject.otherSurvival
dc.titleSurvival at 3, 6 and 12 months in patients diagnosed with Community-Acquired Pneumonia in Colombiaen
dc.title.alternativeSurvival in patients diagnosed with CAP in Colombiaes_CO
dc.typemaster thesises_CO
dc.type.hasVersionpublishedVersiones_CO
dc.rights.accessRightsrestrictedAccesses_CO
dc.subject.armarcPneumonia
dc.subject.armarcRisk factor
dcterms.referencesFerreira-Coimbra J, Sarda C, Rello J. Burden of Community-Acquired Pneumonia and Unmet Clinical Needs. Adv Ther. 2020;37(4):1302–18.
dcterms.referencesSteel HC, Cockeran R, Anderson R, Feldman C. Overview of community-acquired pneumonia and the role of inflammatory mechanisms in the immunopathogenesis of severe pneumococcal disease. Mediators Inflamm. 2013;2013:490346.
dcterms.referencesMartin-Loeches I, Torres A, Nagavci B, Aliberti S, Antonelli M, Bassetti M, Bos LD, Chalmers JD, Derde L, de Waele J, Garnacho-Montero J, Kollef M, Luna CM,
dcterms.referencesMenendez R, Niederman MS, Ponomarev D, Restrepo MI, Rigau D, Schultz MJ, Weiss E, Welte T, Wunderink R. ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia. Intensive Care Med. 2023;49(6):615-632.
dcterms.referencesLosier A, Dela Cruz CS. New testing guidelines for community-acquired pneumonia. Curr Opin Infect Dis. 2022 ;35(2):128-132.
dcterms.referencesKang SH, Jo YH, Lee JH, Jang DH, Kim YJ, Park I. Antibiotic prescription consistent with guidelines in emergency department is associated with 30-day survival in severe community-acquired pneumonia. BMC Emerg Med. 2021;21(1):1–9.
dcterms.referencesBordon J, Wiemken T, Peyrani P, Paz ML, Gnoni M, Cabral P, Venero Mdel C, Ramirez J; CAPO Study Group. Decrease in long-term survival for hospitalized patients with community-acquired pneumonia. Chest. 2010 ;138(2):279-83.
dcterms.referencesCorrales-Medina VF, Madjid M, Musher DM. Role of acute infection in triggering acute coronary syndromes. Lancet Infect Dis. 2010 ;10(2):83-92
dcterms.referencesSaldías Peñafiel F, Román O F, Maturana O R, Díaz P O. Predictors of one year mortality among immunocompetent adults hospitalized for community-acquired pneumonia. Rev Med Chil. 2013;141(2):143–52.
dcterms.referencesSchoenfeld DA. Sample-Size Formula for the Proportional-Hazards Regression Model. Biometrics. 1983 Jun;39(2):499.
dcterms.referencesMandell LA. Community-acquired pneumonia: An overview. Postgrad Med. 2015;127(6):607–15
dcterms.referencesRider AC, Frazee BW. Community-Acquired Pneumonia. Emerg Med Clin North Am. 2018 ;36(4):665-683.
dcterms.referencesohnstone J, Eurich DT, Majumdar SR, Jin Y, Marrie TJ. Long-term morbidity and mortality after hospitalization with community-acquired pneumonia: A populationbased cohort study. Medicine (Baltimore). 2008;87(6):329–34
dcterms.referencesMartínez-Vernaza S, Mckinley E, Soto MJ, Gualtero S. Neumonía adquirida en la comunidad : una revisión narrativa. 2018;(4).
dcterms.referencesTorres A, Peetermans WE, Viegi G, Blasi F. Risk factors for community-acquired pneumonia in adults in Europe: A literature review. Thorax. 2013;68(11):1057–65.
dcterms.referencesCharlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83
dcterms.referencesTokgoz Akyil F, Yalcinsoy M, Hazar A, Cilli A, Celenk B, Kilic O, et al. Prognosis of hospitalized patients with community-acquired pneumonia. Pulmonology. 2018 ;24(3):164–9.
dcterms.referencesRenaud B, Coma E, Hayon J, Gurgui M, Longo C, Blancher M, Jouannic I, Betoulle S, Roupie E, Fine MJ; PNEUMOCOM study investigators. Investigation of the ability of the Pneumonia Severity Index to accurately predict clinically relevant outcomes: a European study. Clin Microbiol Infect. 2007 ;13(9):923-31.
dcterms.referencesCecere LM, Rubenfeld GD, Goss CH. Long-Term Survival after Hospitalization for Community-Acquired and Healthcare-Associated Pneumonia. 2010;98101:128–36.
dcterms.referencesRuiz LA, Serrano L, España PP, Martinez-Indart L, Gómez A, Uranga A, Castro S, Artaraz A, Zalacain R. Factors influencing long-term survival after hospitalization with pneumococcal pneumonia. J Infect. 2019 ;79(6):542-549.
dcterms.referencesWelte T, Torres A, Nathwani D. Clinical and economic burden of communityacquired pneumonia among adults in Europe. Thorax. 2012;67(1):71–9.
dcterms.referencesYoshimoto A, Nakamura H, Fujimura M, Nakao S. Severe community-acquired pneumonia in an intensive care unit: Risk factors for mortality. Intern Med. 2005;44(7):710–6.
dcterms.referencesDupuis C, Sabra A, Patrier J, Chaize G, Saighi A, Féger C, Vainchtock A, Gaillat J, Timsit JF. Burden of pneumococcal pneumonia requiring ICU admission in France: 1-year prognosis, resources use, and costs. Crit Care. 2021 ;25(1):24.
thesis.degree.disciplineFacultad de Medicinaes_CO
thesis.degree.levelMaestría en Epidemiologíaes_CO
thesis.degree.nameMagíster en Epidemiologíaes_CO


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 InternacionalExcepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 Internacional